In addition, FXR agonists, including synthetic bile acids and steroidal and non-steroidal compounds, have gained interest as potential therapeutic agents for various metabolic disorders, including NAFLD, NASH and T2DM. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.